These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6244904)

  • 1. A phase II study of neocarzinostatin (NSC 157365) in malignant hepatoma. An Eastern Cooperative Oncology Group pilot study.
    Falkson G; Von Hoff D; Klaassen D; Du Plessis H; Van Der Merwe CF; Van Der Merwe AM; Carbone PP
    Cancer Chemother Pharmacol; 1980; 4(1):33-6. PubMed ID: 6244904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma.
    Falkson G; MacIntyre JM; Schutt AJ; Coetzer B; Johnson LA; Simson IW; Douglass HO
    J Clin Oncol; 1984 Jun; 2(6):581-4. PubMed ID: 6327926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zinostatin and doxorubicin. A combination phase I study.
    Issell BF; Ginsberg SJ; Comis RL
    Cancer Clin Trials; 1981; 4(3):323-6. PubMed ID: 6269771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of m-AMSA in patients with primary liver cancer.
    Falkson G; Coetzer B; Klaassen DJ
    Cancer Chemother Pharmacol; 1981; 6(2):127-9. PubMed ID: 6895485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase II study of m-AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell bronchogenic carcinoma. An Eastern Cooperative Group Study.
    Ettinger DS; Day R; Ferraro JA; Ruckdeschel JC; Woll JE; Creech RH; Vogl SE
    Am J Clin Oncol; 1983 Apr; 6(2):167-70. PubMed ID: 6299093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and preliminary phase II study of neocarzinostatin.
    Griffin TW; Comis RL; Lokich JJ; Blum RH; Canellos GP
    Cancer Treat Rep; 1978 Dec; 62(12):2019-25. PubMed ID: 221112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neocarzinostatin (NSC 157365) a new cancerostatic compound.
    Legha SS; Von Hoff DD; Rozencweig M; Abraham D; Slavik M; Muggia M
    Oncology; 1976; 33(5-6):265-70. PubMed ID: 141012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of arterial infusion chemotherapy with neocarzinostatin on inoperable hepatoma].
    Sasaki Y; Fujita S; Yoshioka H; Takimoto C; Mitsutani N; Koizumi T
    Gan To Kagaku Ryoho; 1982 May; 9(5):898-905. PubMed ID: 6307185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neocarzinostatin: report of a phase II clinical trial.
    McKelvey EM; Murphy W; Zander A; Bodey GP
    Cancer Treat Rep; 1981; 65(7-8):699-701. PubMed ID: 6454486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of neocarzinostatin in patients with bladder and prostatic cancer: toxicity of a five-day iv bolus schedule.
    Natale RB; Yagoda A; Watson RC; Stover DE
    Cancer; 1980 Jun; 45(11):2836-42. PubMed ID: 6445776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase I study of YM881 (zinostatin stimalamer) suspension by hepatic arterial infusion. Research Group for Intra-arterial Infusion Therapy with YM881].
    Taguchi T; Saito T; Ota J; Nakao I; Ohashi K; Nakamura H; Konno T
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1657-63. PubMed ID: 1651686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Principle and therapeutic effect of lipophilic anticancer agent [SMANCS/lipiodol]: selective targeting with oily contrast medium].
    Maeda H
    Gan To Kagaku Ryoho; 1989 Oct; 16(10):3323-31. PubMed ID: 2552930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of neocarzinostatin in patients with acute leukemia.
    Van Echo DA; Wiernik PH
    Cancer Treat Rep; 1978 Sep; 62(9):1363-5. PubMed ID: 150945
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemotherapy for bladder cancer with neocarzinostatin: evaluation of systemic administration.
    Sakamoto S; Ogata J; Ikegami K; Maeda H
    Eur J Cancer (1965); 1980 Jan; 16(1):103-13. PubMed ID: 6444585
    [No Abstract]   [Full Text] [Related]  

  • 15. [Phase II study of VP-16 (capsule) in solid tumors. A cooperative study].
    Honma T; Ogawa M; Yoshida S; Meguro S; Hirano M; Hoshino A; Shirakawa S; Nakamura T; Fukuoka M; Toki H
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):309-13. PubMed ID: 2982332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Phase II study of YM881 (zinostatin stimalamer) suspension injected into the hepatic artery. Research Group for Intra-arterial Injection Therapy with YM881].
    Taguchi T; Saito T; Ota J; Nakao I; Ohashi K; Nakamura H; Konno T
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1665-75. PubMed ID: 1714707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neocarzinostatin: a phase I clinical trial with five-day intermittent and continuous infusions.
    McKelvey EM; Burgess MA; McCredie KB; Murphy WK; Bodey GP
    Cancer; 1979 Oct; 44(4):1182-8. PubMed ID: 159119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel dosage approach for evaluation of SMANCS [poly-(styrene-co-maleyl-half-n-butylate) - neocarzinostatin] in the treatment of primary hepatocellular carcinoma.
    Seymour LW; Olliff SP; Poole CJ; De Takats PG; Orme R; Ferry DR; Maeda H; Konno T; Kerr DJ
    Int J Oncol; 1998 Jun; 12(6):1217-23. PubMed ID: 9592177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary. A Gynecologic Oncology Group study.
    Thigpen JT; Blessing JA; Arseneau JC; Homesley HD
    Am J Clin Oncol; 1984 Jun; 7(3):261-3. PubMed ID: 6547268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical investigations of neocarzinostatin in Japan.
    Kimura I
    Recent Results Cancer Res; 1978; 63():252-60. PubMed ID: 151899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.